Similar articles

Abstract: Objective: To evaluate the association between p53 codon 72 polymorphism (R72P) and the risk of colorectal liver metastases. Methods: The p53 R72P genotype was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 78 consecutive colorectal cancer patients with liver metastases and 214 age- and sex-matched cases with nonmetastatic colorectal cancer. Results: The R allele of the p53 R72P polymorphism was more frequently found in metastatic cases than in nonmetastatic cases (P=0.075). Carriers of the 72R allele had a 2.25-fold (95% CI (confidence interval)=1.05~4.83) increased risk of liver metastases. On the stratification analysis, 72R-carrying genotype conferred a 3.46-fold (95% CI=1.02~11.72) and a 1.05-fold (95% CI=0.36~3.08) increased risk of liver metastases for p53 overexpression-positive and negative colorectal cancers, respectively. Conclusion: These results demonstrate for the first time that the 72R allele of the p53 polymorphism has an increased risk for liver metastases in colorectal cancers positive for p53 overexpression.

[1] Adachi, Y., Inomata, M., Kakisako, K., Sato, K., Shiraishi, N., Kitano, S., 1999. Histopathologic characteristics of colorectal cancer with liver metastasis. Dis. Colon. Rectum, 42(8):1053-1056.

[2] Anzola, M., Cuevas, N., Lopez-Martinez, M., Saiz, A., Burgos, J.J., de Pancorbo, M.M., 2003. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett., 193(2):199-205.

[3] Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., Numico, G., Comino, A., et al., 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3(4):387-402.

[4] Bosman, F.T., 1995. Prognostic value of pathological characteristics of colorectal cancer. Eur. J. Cancer, 31A(7-8):1216-1221.

[5] Brooks, L.A., Tidy, J.A., Gusterson, B., Hiller, L., O′Nions, J., Gasco, M., Marin, M.C., Farrell, P.J., Kaelin, W.G.Jr., Crook, T., 2000. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res., 60(24):6875-6877.

[6] Burke, D., Allen-Mersh, T.G., 1996. Colorectal liver metastases. Postgrad. Med. J., 72(850):464-469.

[7] Coggi, G., Bosari, S., Roncalli, M., Graziani, D., Bossi, P., Viale, G., Buffa, R., Ferrero, S., Piazza, M., Blandamura, S., et al., 1997. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer, 79(3):425-432.

[8] Dameron, K.M., Volpert, O.V., Tainsky, M.A., Bouck, N., 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265(5178):1582-1584.

[9] de Jong, K.P., Gouw, A.S., Peeters, P.M., Bulthuis, M., Menkema, L., Porte, R.J., Slooff, M.J., van Goor, H., van den Berg, A., 2005. p53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin. Cancer Res., 11(11):4067-4073.

[10] Dumont, P., Leu, J.I., Della Pietra, A.C.3rd, George, D.L., Murphy, M., 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet., 33(3):357-365.

[11] Furihata, M., Takeuchi, T., Matsumoto, M., Kurabayashi, A., Ohtsuki, Y., Terao, N., Kuwahara, M., Shuin, T., 2002. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin. Cancer Res., 8(5):1192-1195.

[12] Ghadjar, P., Coupland, S.E., Na, I.K., Noutsias, M., Letsch, A., Stroux, A., Bauer, S., Buhr, H.J., Thiel, E., Scheibenbogen, C., et al., 2006. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J. Clin. Oncol., 24(12):1910-1916.

[13] Herynk, M.H., Zhang, J., Parikh, N.U., Gallick, G.E., 2007. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J. Exp. Ther. Oncol., 6(3):205-217.

[14] Hsieh, L.L., Huang, T.H., Chen, I.H., Liao, C.T., Wang, H.M., Lai, C.H., Liou, S.H., Chang, J.T., Cheng, A.J., 2005. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br. J. Cancer, 92(1):30-35.

[15] Kang, S.M., Maeda, K., Onoda, N., Chung, Y.S., Nakata, B., Nishiguchi, Y., Sowa, M., 1997. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int. J. Cancer, 74(5):502-507.

[16] Kastrinakis, W.V., Ramchurren, N., Rieger, K.M., Hess, D.T., Loda, M., Steele, G., Summerhayes, I.C., 1995. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene, 11(4):647-652.

[17] Kawaguchi, H., Ohno, S., Araki, K., Miyazaki, M., Saeki, H., Watanabe, M., Tanaka, S., Sugimachi, K., 2000. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res., 60(11):2753-2755.

[18] Kieser, A., Weich, H.A., Brandner, G., Marme, D., Kolch, W., 1994. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9(3):963-969.

[19] Kimura, O., Sugamura, K., Kijima, T., Makino, M., Shirai, H., Tatebe, S., Ito, H., Kaibara, N., 1996. Flow cytometric examination of p53 protein in primary tumors and metastases to the liver and lymph nodes of colorectal cancer. Dis. Colon. Rectum, 39(12):1428-1433.

[20] Kuramochi, H., Hayashi, K., Uchida, K., Miyakura, S., Shimizu, D., Vallbohmer, D., Park, S., Danenberg, K.D., Takasaki, K., Danenberg, P.V., 2006. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin. Cancer Res., 12(1):29-33.

[21] Langerod, A., Bukholm, I.R., Bregard, A., Lonning, P.E., Andersen, T.I., Rognum, T.O., Meling, G.I., Lothe, R.A., Borresen-Dale, A.L., 2002. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol. Biomarkers Prev., 11(12):1684-1688.

[22] Lanham, S., Campbell, I., Watt, P., Gornall, R., 1998. p53 polymorphism and risk of cervical cancer. Lancet, 352(9140):1631.

[23] Lee, J.M., Shun, C.T., Wu, M.T., Chen, Y.Y., Yang, S.Y., Hung, H.I., Chen, J.S., Hsu, H.H., Huang, P.M., Kuo, S.W., et al., 2006. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat. Res., 594(1-2):181-188.

[24] Liang, J.T., Huang, K.C., Jeng, Y.M., Lee, P.H., Lai, H.S., Hsu, H.C., 2004. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br. J. Surg., 91(3):355-361.

[25] Lin, H.M., Chatterjee, A., Lin, Y.H., Anjomshoaa, A., Fukuzawa, R., McCall, J.L., Reeve, A.E., 2007. Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol. Rep., 17(6):1541-1549.

[26] Manfredi, S., Lepage, C., Hatem, C., Coatmeur, O., Faivre, J., Bouvier, A.M., 2006. Epidemiology and management of liver metastases from colorectal cancer. Ann. Surg., 244(2):254-259.

[27] Marin, M.C., Jost, C.A., Brooks, L.A., Irwin, M.S., O′Nions, J., Tidy, J.A., James, N., McGregor, J.M., Harwood, C.A., Yulug, I.G., et al., 2000. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet., 25(1):47-54.

[28] Ogawa, M., Ikeuchi, K., Watanabe, M., Etoh, K., Kobayashi, T., Takao, Y., Anazawa, S., Yamazaki, Y., 2005. Expression of matrix metalloproteinase 7, laminin and type IV collagen-associated liver metastasis in human colorectal cancer: immunohistochemical approach. Hepatogastroenterology, 52(63):875-880.

[29] Papadakis, E.D., Soulitzis, N., Spandidos, D.A., 2002. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br. J. Cancer, 87(9):1013-1018.

[30] Perez, L.O., Abba, M.C., Dulout, F.N., Golijow, C.D., 2006. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J. Gastroenterol., 12(9):1426-1429.

[31] Schneider-Stock, R., Mawrin, C., Motsch, C., Boltze, C., Peters, B., Hartig, R., Buhtz, P., Giers, A., Rohrbeck, A., Freigang, B., et al., 2004a. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am. J. Pathol., 164(4):1233-1241.

[32] Schneider-Stock, R., Boltze, C., Peters, B., Szibor, R., Landt, O., Meyer, F., Roessner, A., 2004b. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia, 6(5):529-535.

[33] Shinji, S., Naito, Z., Ishiwata, S., Ishiwata, T., Tanaka, N., Furukawa, K., Suzuki, H., Seya, T., Matsuda, A., Katsuta, M., et al., 2006. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol. Rep., 15(3):539-543.

[34] Tada, M., Furuuchi, K., Kaneda, M., Matsumoto, J., Takahashi, M., Hirai, A., Mitsumoto, Y., Iggo, R.D., Moriuchi, T., 2001. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis, 22(3):515-517.

[35] Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L., Matlashewski, G., 1999. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol., 19(2):1092-1100.

[36] Vermeulen, P.B., Roland, L., Mertens, V., van Marck, E., de Bruijn, E.A., van Oosterom, A.T., Dirix, L.Y., 1996. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvasc. Res., 51(2):164-174.

[37] Zhu, Z.Z., Cong, W.M., Liu, S.F., Xian, Z.H., Wu, W.Q., Wu, M.C., Gao, B., Hou, L.F., Zhu, G.S., 2005. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett., 229(1):77-83.